--- title: "Lantern Pharma raises capital, plans AI platform spinoff" type: "News" locale: "en" url: "https://longbridge.com/en/news/286480334.md" description: "Lantern Pharma (LTRN) has raised approximately $4.4 million through a registered direct offering and concurrent private placement to support its oncology pipeline and plans to spin off its AI platform, withZeta.ai, into a separate entity. The move aims to enhance liquidity and strategic flexibility for stakeholders. The company has also outlined measures to limit dilution and has received a Buy rating from analysts with a $25.00 price target, although concerns about financial performance persist. Lantern Pharma focuses on AI-driven precision oncology and is listed on Nasdaq." datetime: "2026-05-14T23:24:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286480334.md) - [en](https://longbridge.com/en/news/286480334.md) - [zh-HK](https://longbridge.com/zh-HK/news/286480334.md) --- # Lantern Pharma raises capital, plans AI platform spinoff ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks An announcement from Lantern Pharma ( (LTRN) ) is now available. On May 12, 2026, Lantern Pharma entered into a securities purchase agreement with institutional investors for a registered direct offering of common shares and pre-funded warrants, which closed on May 14, 2026 and generated approximately $4.4 million in gross proceeds for working capital and general corporate purposes. In a concurrent private placement, the company issued additional warrants, granted investors participation rights in future equity financings of a planned AI-focused subsidiary built around withZeta.ai, imposed a two-year ban on variable-rate financings, suspended use of its existing at-the-market facility, and outlined plans to separate its AI platform into an independently financed, potentially exchange-listed business under CEO Panna Sharma, aiming to unlock distinct valuation and strategic flexibility for stakeholders. On May 13, 2026, Lantern Pharma also detailed warrant economics, placement-agent compensation, and investor ownership caps designed to limit immediate dilution while leaving open up to $4.85 million in potential future proceeds from warrant exercises. The move signals an effort to shore up liquidity for its oncology pipeline while positioning its withZeta.ai technology as a standalone AI co-scientist platform for investors and biotech executives, potentially enhancing the company’s industry positioning at the intersection of AI and drug development. The most recent analyst rating on (LTRN) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Lantern Pharma stock, see the LTRN Stock Forecast page. **Spark’s Take on LTRN Stock** According to Spark, TipRanks’ AI Analyst, LTRN is a Neutral. The score is primarily constrained by weak financial performance (no revenue, recurring losses, and ongoing cash burn). Technicals also weigh on the rating given the stock’s position below key moving averages. Valuation is only a modest offset because the negative P/E is not informative and there is no dividend support. To see Spark’s full report on LTRN stock, click here. **More about Lantern Pharma** Lantern Pharma Inc. is a clinical-stage, AI-driven precision oncology company listed on Nasdaq that focuses on transforming the cost and pace of oncology drug discovery and development. Its proprietary RADR platform, deployed through withZeta.ai, applies machine learning to vast oncology datasets to identify biomarker signatures and advance small-molecule and antibody-drug conjugate candidates for hard-to-treat solid and hematologic cancers. **Average Trading Volume:** 617,283 **Technical Sentiment Signal:** Sell **Current Market Cap:** $23.29M For an in-depth examination of LTRN stock, go to TipRanks’ Overview page. ### Related Stocks - [LTRN.US](https://longbridge.com/en/quote/LTRN.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) ## Related News & Research - [Lantern Pharma shifts LP-300 Phase 2 HARMONIC trial to single-arm L858R focus](https://longbridge.com/en/news/286903851.md) - [ImmunityBio reports higher complete response rates for ANKTIVA plus BCG in AUA analysis](https://longbridge.com/en/news/286903126.md) - [](https://longbridge.com/en/news/286807703.md) - [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md) - [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md)